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Background
Advances in instrumentation and progress in immuno-oncology are driving a revolution 
in cancer care. New cancer treatment methods are emerging–targeted immunotherapies 
are among the most promising treatment options. Checkpoint blocking antibodies are 
currently providing stable cures to a subset of patients that could not be helped previ-
ously [1]. Chimeric antigen receptor (CAR) T cell/adoptive T cell therapies have been 
shown effective in some terminally ill patients [2]. Neoantigens are newly formed pro-
tein antigens that occur in individual patients, either from somatic mutations of genes 
or viral genes incorporated in the infected cell genome. These freshly emerged genes 
encode proteins that contain new T cell epitopes capable of inducing tumor-specific 
T cell recognition. Furthermore, it was demonstrated that the recognition of even a 
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small number of epitopes by T cells might be sufficient to reject tumors in terminally ill 
patients through adoptive T cell therapy [3, 4].
T cells recognize antigens through T cell receptor (TCR), a surface protein composed 
of multiple peptide chains. A TCR has such high antigen specificity that it can recog-
nize its cognate targets at a level of single amino acid difference. A highly diverse rep-
ertoire of TCR sequences ensures the effectiveness of the adaptive immune system [5, 
6]. It was shown that T cell repertoire could serve as a biomarker of immune responses 
in cancer patients [7, 8]. TCR sequences with validated cognate antigens are essential 
for cell-based vaccine design. Vaccines that target neoantigens and personalized can-
cer immunotherapies are considered as the current clinical and research frontier in 
immuno-oncology [9, 10].
Tumor derived antigens that induce productive antitumor immune responses are 
known as tumor antigens (TAs) [11]. TAs can be divided into two main groups, tumor-
specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs may be mutated 
tumor neoantigens [12], cancer-testis antigens [13], or oncofetal proteins [14]. TSAs are 
exclusively found in tumors and are not expressed in normal tissues. TAAs are normal 
proteins that are overexpressed in tumor cells as compared to the expression level in 
healthy cells [15]. Neoantigens are TAs that are no longer self. They are not tolerated by 
T cell immunity and are exclusively tumor specific. TAs have been extensively studied 
and offer high promise for cancer therapeutics design and serve as cancer diagnosis tar-
gets [9, 10, 16, 17]. The therapeutic landscape of cancer has recently been transformed 
by the emergence of effective immunotherapies [18, 19]. Despite these advances, any 
one form of immunotherapy studied and used to date was shown to benefit only a sub-
set of patients. These immunotherapies facilitate T cell mediated immunity against the 
tumors. However, we lack an understanding of what defines the specificity of protec-
tive T cell immune responses they generate. Correct identification and cataloging of T 
cell antigens that aid tumor rejection will allow the development of highly effective per-
sonalized cancer vaccine immunotherapies and understand the protection mechanism. 
Current epitope prediction algorithms only forecast HLA processing and presentation 
but cannot predict antigenicity. They produce large numbers of positives that are bio-
chemically active but functionally inert [20]. Because not all HLA presented epitopes are 
recognized by T cells, their inclusion in the vaccines and immunotherapies may reduce 
immunotherapy effectiveness. Validated data sets of T cell epitopes with the associated 
HLA restriction may also allow the development of improved epitope prediction algo-
rithms [20, 21]. TCR sequences specific for TAs can be utilized to generate antitumor T 
cells for adoptive T cell therapy or as templates for building models of TCR-antigen rec-
ognition for neoantigens that show high similarity to known immune response targets.
To support the development of rationally designed epitope-based cancer vaccines, 
we previously developed TANTIGEN, a comprehensive web-based database catalog-
ing more than 1000  T cell epitopes and HLA ligands from 292 different tumor T cell 
antigens [22]. In the current build, TANTIGEN 2.0 [23], we extended the coverage of 
immune response targets in the original set of TAs, added more than 100 new TAs, 
and a selection of their T cell epitopes and ligands. All T cell epitopes and neoepitopes 
included in TANTIGEN 2.0 have been experimentally validated.
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Implementation
Data collection, annotation, and organization
We assembled TANTIGEN 2.0 by compiling the new data from the Cancer Antigenic 
Peptide Database [24] and recent publications reporting neoepitopes and neoantigens. 
Previously we included mRNA expression information of TAs by providing EST profiles 
from UniGene. However, NCBI retired the UniGene web pages in July 2019. Large scale 
open-access efforts, such as the Cancer Genome Atlas (TCGA) and the Human Protein 
Atlas (HPA), provided data for genome-wide expression analysis of individual genes in 
different tissues and cancers [25, 26]. The Human Pathology Atlas that was created as 
a part of the Human Protein Atlas program analyzed and cataloged expression profiles 
at both RNA and protein levels. Protein expression data are shown in normal tissue and 
major human cancers [27]. In TANTIGEN 2.0, we utilized data from the HPA to enrich 
available information on TAs. TCR sequences were collected from McPAS-TCR, a TCR 
sequence database associated with various pathologies and antigens based on published 
literature [28]. It contains more than 5,000 sequences of TCRs associated with multi-
ple pathologic conditions, including cancer and their respective antigens in humans and 
mice. To ensure data integrity and avoid the proliferation of data errors from external 
databases, we manually checked the data against the original publications. For exam-
ple, in McPAS-TCR, an HLA-A*0201 restricted T cell epitope YLEPGPVTA (IEDB ID: 
74,638) was mistakenly described as A*01. The error was corrected when data were inte-
grated into TANTIGEN 2.0.
Bioinformatics tools
A set of bioinformatics tools has been integrated into TANTIGEN 2.0 to streamline data 
analysis. Users can look for antigens, epitopes, and HLA ligands using keyword searches. 
Sequence similarity searches can be performed using BLAST (Basic Local Alignment 
Search Tool) [29]. Sequence homology can be examined using multiple sequence align-
ment by MAFFT [30]. On-the-fly HLA binding prediction tools for 15 common HLA 
class I and class II alleles were integrated into TANTIGEN 2.0. They facilitate analysis of 
known immunogenicity in conjunction with predicted HLA binding and the prediction 
of additional potential epitopes. TANTIGEN 2.0 has a set of visualization tools that dis-
play the locations of peptides within their parent proteins. For each protein that contains 
point mutations, an interactive visualization tool shows a map of mutations in the tumor 
antigen sequences to provide a global view of all reported mutations for a given tumor 
antigen. For neoantigen entries, both the neoantigen fragment and the native sequence 
(called reference sequence) are included.
Webserver
The TANTIGEN webserver interface was constructed using the KB-builder framework, 
which streamlines the development and deployment of web-accessible immunological 
databases [31]. TANTIGEN 2.0 serves as an integrator of relevant information critical 
for the design of highly personalized cancer vaccines and immunotherapies.
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Results
In TANTIGEN 2.0, we cataloged more than 1000 validated tumor T cell epitopes and 
over 500 HLA binding ligands (1,676 in total). The database hosts more than 4,000 anti-
gen variants from 403 unique TAs reported in literature. Each record contains the infor-
mation on tumor antigen sequence, variants (splice isoforms and mutation variants), 
known T-cell epitopes and HLA ligands, TCR information (if available), and literature 
references.
Around 50% of the antigens (201 out of 403) have substitution mutations, with about 
25% (95) having more than one. The antigens have more than 100 substitution mutations 
include TP53 (1,311 mutations), CDKN2A (239), EGFR (169), CTNNB1 (111), TYR 
Fig. 1 Example pages with neoantigen and neoepitope information: a HER2 neoantigen with a substitute 
mutation H473Y; b Part of the mutation Map; c HLA A*0201 restricted neoepitope; d On-the-fly HLA binding 
prediction with side-by-side comparison with the reference sequence. Predicted weak and strong binders are 
highlighted in green and magenta respectively; e TCR information
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(111), and APC (103). The TA variants include 879 full-length sequences, 243 partial 
sequences, and 3,175 short fragments resulted from identified substitution mutations. 
Most defined short fragments are 41 aa long sequences with the mutation in the middle 
(position 21). Sometimes it is impossible to place the mutation position in the middle of 
the sequence. For example, in Ag000048, the mutation is at position 12 in the reference 
antigen. The length of these fragments is kept the same at 41. The reference sequence 
fragment is included for comparison with the mutated fragment; the mutation site is 
highlighted (Fig. 1a). The substitution mutation H473Y resulted in an A*0201 restricted 
neoepitope, as shown in Fig. 1b, c. The HLA binding prediction comparison in Fig. 1d 
shows that the peptide becomes a strong HLA-A*0201 binder instead of a weaker one 
due to the mutation. The TCR information for the neoepitope is shown in Fig. 1d.
Conclusions
TANTIGEN 2.0 provides a rich data resource for tumor associated epitope and 
neoepitope discovery studies. It hosts more than 4,000 antigen variants from 403 unique 
TAs (a 38% increase comparing to TANTIGEN) and 1,676  T cell epitopes and HLA 
ligands (a 46% increase). TCR information for some T cell epitopes is included too. Inte-
grated computational analysis tools in TANTIGEN 2.0 enable users to combine data 
Fig. 1 continued
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and domain knowledge, use tailored bioinformatics tools, and simulate experiments. It 
represents a rich information resource for the study of cancer immunology and immu-
notherapy. All data and tools described here are available in TANTIGEN 2.0, an interac-
tive open-access database (http://proje cts.met-hilab .org/tadb). The primary purpose of 
TANTIGEN2.0 is to support the design of neoantigen vaccine-based cancer immuno-
therapies. Immunological peptides from cancer-causing human viruses, such as Epstein-
Barr virus (EBV), Human Papillomavirus (HPV), and Merkel Cell Polyomavirus (MCV), 
were not included in TANTIGEN. We developed EBVdb, HPVdb, and MCVdb to sup-
port studies on T cell immunology of EBV, HPV, and MCV [32–34].
Availability and requirements
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